Urodynamics
Urodynamic studies in all groups revealed the highest bladder compliance in controls and the lowest compliance in both pBOO groups in the 7th week post-urethral ligation (48.57 8.61 vs. 21.00 3.87 μL/cm H2O, respectively, p < 0.01). After subjection to two injections of USCs, compliance gradually improved in the pBOO+USCs group in the 15th week compared with that in the pBOO group (38.35 2.81 vs. 16.57 4.69 μL/cm H2O, respectively, p < 0.01) and compliance was found to be similar to that of controls in the 19th week (48.50 7.28 vs. 50.07 8.04 μL/cm H2O, respectively, p = 0.89) (Fig. 1A). The maximal voiding pressure in the pBOO group was significantly lower than that in the control group in the 7th week (24.32 3.22 vs. 46.80 10.17 cm H2O, respectively, p < 0.01), whereas pBOO+USCs gradually presented with an increasing pressure from the 15th week (38.31 5.21 vs. 22.61 2.60 cm H2O, respectively, p < 0.01) (Fig. 1B). End-filling pressure in pBOO rats was higher than that in controls (10.96 2.07 vs. 6.84 1.80 cm H2O, respectively, p = 0.006), and it increased from the 7th week to 19th week (10.96 2.07 in 7th week vs. 16.15 1.68 cm H2O in 19th week, p < 0.01), whereas the pressure in pBOO+USCs rats decreased to the control level (9.03 0.99 vs. 7.26 1.94 cm H2O, respectively, p = 0.359) in the 15th week (Fig. 1C). All pBOO and pBOO+USCs rats demonstrated significantly higher residual volume than control rats (0.70 0.11 vs. 1.36 0.19 mL, respectively, in the 7th week [p < 0.01]); however, USCs considerably suppressed the upward trend from the 15th week (1.26 0.12 vs. 1.93 0.10 mL, p < 0.01) (Fig. 1D). Moreover, pBOO rats exhibited lower voided volume than control rats in the 7th week (238.77 27.11 vs. 337.84 21.49 μL, p < 0.01); however, the pBOO+USCs group exhibited an increasing trend and finally demonstrated similar voided volume as the control group in the 19th week (340.75 16.93 vs. 316.51 16.23 μL, respectively, p = 0.119) (Fig. 1E). Additionally, a significant increase in the bladder capacity was observed in all pBOO rats compared with that in the control (1.54 0.14 vs. 1.04 0.14 mL, respectively, p < 0.01). Although USCs reversed the trend in pBOO+USCs group from the 15th week (1.59 0.23 vs. 2.17 0.17 mL, p < 0.01), the bladder capacity did not decrease to the level of the control (1.52 0.27 vs. 1.08 0.16 mL, respectively, p < 0.01) (Fig. 1F). Representative cystometrograms of three rat groups at 7, 11, 15, and 19 weeks after urethral ligation have been depicted in Fig. 1G.
Histology and TUNEL assay
H&E staining revealed that the bladder wall thickness was higher, the urothelium was flatter, and structural damage of detrusor smooth muscle was worse in the pBOO group than those observed in the control group; however, treatment with USCs significantly alleviated these histological changes (Fig. 2A). Masson’s trichrome staining revealed the presence of increased collagen content, disorderly and loosely arranged detrusor muscle bundles, and an evidently widened gap between muscle bundles in the pBOO group compared with the control group and the pBOO+USCs group (Fig. 2B). There was a marked increase in the number of TUNEL-positive cells in the pBOO group compared with the control group, whereas USC treatment significantly decreased the number of apoptotic cells in the bladder (Fig. 2C).
Assessment of detrusor muscle contractility
In the detrusor tension tests, the bladder detrusor contraction amplitudes of pBOO rats were significantly lower than those of control rats. Carbochol elevated the contraction amplitudes at different concentrations (10-6 to 10-4 M) in the three groups, but the bladder detrusor of pBOO rats exhibited the lowest sensitivity to carbochol. The effect of carbochol on the amplitudes of contraction in pBOO+USCs rats was significantly higher than that in pBOO rats (4.58 0.89 vs. 2.85 0.23 mM, respectively, p < 0.01); however, it was lower than that in control rats (4.58 0.89 vs. 6.04 0.26 mM, respectively, p < 0.01) (Fig. 2D).
Bioinformatics analysis of miRNA–mRNA
Bioinformatics analysis revealed differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) in the bladder wall tissue among the control, pBOO, and pBOO+USCs groups in rats. Below, we have provided results for miRNAs and mRNAs that were regulated in the pBOO and USC treatment relative to controls. The comparisons are pBOO relative to the control group and pBOO+USCs relative to the pBOO group.
The volcano plots in Figure 3a and b show DEMs in rat bladder wall tissues of the control, pBOO, and pBOO+USCs groups. The distribution of all miRNAs with respect to significance (y-axis) vs. foldchange (x-axis) has been illustrated using the volcano plot. Compared with the control group, it was noted that the present study helped identify 62 DEMs (40 upregulated and 22 downregulated) and 1686 DEGs (981 upregulated and 705 downregulated) in the pBOO group. Compared with the pBOO group, we identified 42 DEMs (25 upregulated and 17 downregulated) and 757 DEGs (241 upregulated and 516 downregulated) in the pBOO+USCs group. The expression of eight DEMs, which were upregulated in pBOO rats relative to control rats, was reversed via USC treatment (Fig. 3).
Five of the eight DEMs, namely miR-142-3p, miR-142-5p, miR-187-3p, miR-503-5p, and 17_19667_star, presented with upregulated expression in pBOO rats (Fig. 3A) and the expression level was downregulated by USC treatment (Fig. 3B). The Venn diagrams illustrating downregulated mRNAs expressed in rats from pBOO vs. control group (pBOO vs. ctrl mRNA_lo) and upregulated mRNAs expressed in rats from pBOO+USCs vs. pBOO group (pBOO+USCs vs. pBOO mRNA_up), and the target genes of the above-mentioned five DEMs, helped identify three DEGs (Fig. 3).
Three of the eight DEMs, namely miR-9a-3p, miR-9a-5p, and 1_1401, exhibited downregulated expression in pBOO rats (Fig. 3A) and upregulated expression via USC treatment (Fig. 3B). Similarly, the Venn diagrams illustrating upregulated mRNAs expressed in rats from pBOO vs. control group (pBOO vs. ctrl mRNA_up) and downregulated mRNAs expressed in rats from pBOO+USCs vs. pBOO group (pBOO+USCs vs. pBOO mRNA_lo), and the target genes of the above-mentioned three DEMs, helped identify 17 DEGs (Fig. 3). The changes in the levels of these DEMs in the three groups are shown in the gene trend map in Figure 3C and D.
Following the above-mentioned analysis, a miRNA–gene interaction network was constructed by integrating data on the target genes with DEGs. As shown in Figure 4A, the pBOO and USC-associated DEM–DEG interaction network was constructed, which comprised 23 nodes, including 4 that were DEMs, and 22 connections. miR‑9a-3p and miR‑9a-5p were determined as the two largest nodes of the four DEMs and established interactions with 13 and 5 DEGs, respectively.
GO analysis revealed that the most significantly enriched GO terms that corresponded to the above-mentioned target DEGs were “superoxide-generating NADPH oxidase activity” (ontology: MF), “NADPH oxidase complex” (ontology: CC) and “semaphorin-plexin signaling pathway involved in axon guidance” (ontology: BP) (Fig. 4B).
Furthermore, KEGG analysis revealed that multiple significant pathways were enriched, which were primarily associated with leukocyte transendothelial migration, chemokine signaling pathway, cytokine–cytokine receptor interaction, necroptosis, nucleotide-binding and oligomerization domain (NOD)-like receptor signaling pathway, and apoptosis signaling pathway (Fig. 4C).